KIR3DL1 and neuroblastoma: In both clinical trials, patients with KIR3DL1+/A-Bw4+ or with KIR3DL1+/B-Bw4-T80+ genotypes randomized to neuroblastoma immunotherapy or FL maintenance immunotherapy had better outcome versus those randomized to no immunotherapy for neuroblastoma or non-maintenance for FL.